GlassScriptPhysician profile
Trisha M Estes
NPI 1811586522
$4,024.58
in general payments reported to CMS, 2019-2025
33 companies · $789 in 2025
The $789 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $634 · 2023: $1,235 · 2024: $1,366 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,390.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,238.65 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $568.96 | 2022-2025 | Rexulti, Jynarque, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $334.46 | 2022-2025 | Breztri, Airsupra, Fasenra |
| Pfizer INC. | $320.76 | 2023-2025 | |
| Lilly USA, LLC | $164.23 | 2022-2025 | Mounjaro, Kisunla, Zepbound |
| Novo Nordisk INC | $132.33 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $107.86 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $94.58 | 2023-2025 | |
| Antares Pharma, INC. | $88.77 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Organon LLC | $88.22 | 2022-2023 | Nexplanon |
| Lundbeck LLC | $79.26 | 2023-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $79.05 | 2024-2025 | Fanapt, Hetlioz |
| Grifols USA, LLC | $77.60 | 2022-2024 | Prolastin-C Liquid |
| Amgen INC. | $77.60 | 2022-2025 | Evenity, Prolia, Prolia |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.05 | 2022-2025 | Caplyta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $66.51 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $59.39 | 2023-2025 | Opsumit, Uptravi |
| Exact Sciences Corporation | $58.51 | 2023-2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $42.16 | 2025 | |
| Axsome Therapeutics, INC. | $32.96 | 2025 | Auvelity |
| Seqirus USA INC | $28.60 | 2024 | Fluad, Flucelvax |
| Janssen Pharmaceuticals, INC | $28.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.70 | 2022 | |
| Viiv Healthcare Company | $20.39 | 2023 | Apretude |
| Bayer Healthcare Pharmaceuticals INC. | $19.29 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $18.21 | 2023 | |
| Merck Sharp & Dohme LLC | $17.83 | 2024 | Gardasil, Vaxelis, Gardasil 9 |
| Acella Pharmaceuticals, LLC | $17.68 | 2025 | NP Thyroid 60 |
| Kowa Pharmaceuticals America, INC. | $14.37 | 2023 | Seglentis, Livalo |
| Coopersurgical, INC. | $14.20 | 2025 | Paragard T 380a |
| Noven Therapeutics, LLC | $13.81 | 2024 | Secuado, Xelstrym |
| Esperion Therapeutics, INC. | $13.62 | 2024 | Nexletol |
| Philips North America LLC | $12.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trisha Estes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.